Jump to content

Hikma Pharmaceuticals

From Wikipedia, the free encyclopedia

Hikma Pharmaceuticals plc
Company typePublic
IndustryPharmaceutical
Founded1978; 46 years ago (1978)
Jordan
FounderSamih Darwazah Edit this on Wikidata
HeadquartersLondon, England, UK
Key people
ProductsAmoclan
Prograf
Suprax
RevenueIncrease US$2,875 million (2023)[1]
Increase US$707 million (2023)[1]
Increase US$192 million (2023)[1]
Number of employees
8,800 (2024)[2]
Websitewww.hikma.com

Hikma Pharmaceuticals plc is a British multinational pharmaceutical company with headquarters in London, UK that manufactures non-branded generic and in-licensed pharmaceutical products. It was founded by Samih Darwazah in Amman, Jordan in 1978. It is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index.

History

[edit]

The company was founded in 1978 by Samih Darwazah in Amman, Jordan.[3] In August 1996 it became the first Arab company to export pharmaceutical products to the United States.[4] It was first listed on the London Stock Exchange in 2005.[3] Recent acquisitions include Instituto Biochimico Pavese Pharma in Italy in 2005[5] and Jazeera Pharmaceutical Industries in Saudi Arabia in 2006.[3] In 2007 the company went on to buy APM in Jordan,[6] Alkan Pharma in Egypt, APM and Al Jazeera Pharma in Saudi Arabia,[6] Thymoorgan in Germany,[3] and Ribosepharm in Germany.[3] It started to acquire Baxter Healthcare Corporation's US generic injectables business, Multi-Source Injectables or MSI, and completed the transaction in May 2011.[7]

In October 2011, Hikma Pharmaceuticals entered the Moroccan market through the acquisition of Promopharm, the ninth largest pharmaceutical manufacturer in Morocco.[8] Hikma also inaugurated the Al Dar Al Arabia Pharmaceutical Manufacturing Company in Algeria in 2011. The Algerian pharmaceutical company is Hikma’s second venture in Algeria after Hikma Pharma Algeria.[9]

In 2011 the company won the ICSA / Hermes Transparency in Governance Award for the best audit disclosure for a FTSE 250 company.[10]

Hikma expanded its existing presence in the Egyptian market through the acquisition of the Egyptian Company for Pharmaceuticals and Chemical Industries (EPCI) in 2012.[11] In September 2013, Hikma announced expansion into Sub-Saharan Africa with a 50:50 joint venture agreement with MIDROC Pharmaceuticals Limited, to enter the Ethiopian pharmaceutical market.[12]

On 28 May 2014, Hikma Pharmaceuticals agreed to acquire assets from the U.S. generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million, boosting its presence in the injected medicine market.[13]

In June 2020, Boehringer announced it would sell off part of its stake in London-listed Hikma Pharmaceuticals (28 million out of a 40 million share holding) for around $800 million.[14]

Operations

[edit]
Hikma Pharmaceuticals' head office in Hanover Square in London (on the left)

Hikma Pharmaceutical’s operations span 29 manufacturing plants in 10 countries: United States, Portugal, Italy, Jordan, Saudi Arabia, Algeria, Germany, Egypt, Morocco, and Tunisia.[15]

Business segments

[edit]

Branded

[edit]

Hikma’s branded business segment comprises the development and sales of branded generics and in-licensed patented products in the MENA region. Hikma has 499 products in 1,256 dosage strengths. Top products include Actos, Amoclan, Blopress, Omnicef, Prograf, and Suprax.[16]

Injectables

[edit]

Hikma sells specialized injectable products in the US, Europe and MENA including argatroban, fentanyl, phenylephrine, robaxin, and iron gluconate. The company sells 200 products in 379 dosage forms and strengths.[16]

Generics

[edit]

Hikma’s oral generic products are sold in the US and include such products as amoxicillin, cephalexin, doxycycline, methocarbamol, and prednisone.[16]

See also

[edit]

References

[edit]
  1. ^ a b c "Preliminary Results 2023" (PDF). Hikma Pharmaceuticals. Retrieved 22 February 2024.
  2. ^ "Hikma in the US". Hikma Pharmaceuticals. Retrieved 11 February 2024.
  3. ^ a b c d e "Our History". Hikma Pharmaceuticals. Archived from the original on 25 July 2010.
  4. ^ "Economy - Sectoral Analysis". kinghussein.gov.jo. Retrieved 6 March 2015.
  5. ^ "Jordanian Pharma Major Buys Into An American Healthcare Startup". INC Arabia. 24 October 2016. Retrieved 18 April 2017.
  6. ^ a b "Hikma Annual Report 2007 Page 15" (PDF). Archived from the original (PDF) on 24 July 2008. Retrieved 14 September 2008.
  7. ^ "Hikma Pharmaceuticals Plc Completes Acquisition of Baxter Healthcare Corporation's Multi-Source Injectables Business". Reuters. Archived from the original on 18 October 2012. Retrieved 3 May 2011.
  8. ^ Hikma Pharmaceuticals PLC (3 October 2011). "Hikma Enters the Moroccan Market Through the Acquisition of 63.9% of Promopharm and... -- LONDON, October 3, 2011 /PRNewswire/ --". prnewswire.com. Retrieved 6 March 2015.
  9. ^ "Hikma expands in Algeria with Al Dar Al Arabia acquisition". Manufacturing Chemist. 15 April 2011. Retrieved 18 April 2017.
  10. ^ "Login - Evaluate". evaluatepharma.com. Retrieved 6 March 2015.
  11. ^ "Hikma expands in Egypt with EPCI acquisition". pmlive.com. 10 January 2013. Retrieved 6 March 2015.
  12. ^ "Hikma sets up JV to enter Ethiopia". PharmaTimes. 18 September 2013. Retrieved 18 April 2017.
  13. ^ "Hikma buys Boehringer injectable drugs business for up to $300 mln". Reuters. 28 May 2014. Retrieved 6 March 2015.
  14. ^ "Hikma's major investor to exit nearly 1 billion pound stake in drugmaker". 22 June 2020. Archived from the original on 23 June 2020 – via uk.reuters.com.
  15. ^ "Our global presence". Retrieved 18 April 2017.
  16. ^ a b c "Products". Hikma Pharmaceuticals. Retrieved 18 April 2017.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Hikma_Pharmaceuticals&oldid=1258635629"